On Monday, Ampio Pharmaceuticals Inc (NYSEMKT:AMPE)’s shares declined -65.82% to $2.69.
Ampio Pharmaceuticals Inc (AMPE) declared that the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control even though there was a statistically noteworthyreduction in pain contrast to baseline for patients receiving Ampion™
Ampio Pharmaceuticals launched the Phase III program for AmpionTM – a low molecular weight filtrate of an FDA approved biologic – to treat pain due to osteoarthritis (OA) of the knee. Each patient received three 4ml intra-articular injections of Ampion™or the saline placebo, one at baseline, the second at two weeks and the third at four weeks. In OA, saline is known to be a partial therapeutic and not a true placebo, but has been the control used in all published OA drug trials.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the accessible phosphate needed for the inflammation process; and decreasing vascular permeability.
FARO Technologies, Inc. (NASDAQ:FARO)’s shares dropped -25.90% to $46.11.
FARO Technologies, Inc. (FARO) declared preliminary, unaudited sales for its first quarter of 2015. The Company anticipates to report quarterly sales of about $70 million for the first quarter ended March 28, 2015, a decrease of about 5% from the same quarter last fiscal year. This decrease is principally due to the following negative effects, which were partially offset by strong units sold growth in the Europe/Africa region of Laser Tracker and Laser Scanner:
- negative foreign exchange influence of about $7 million driven primarily by the decline in the Euro and Yen relative to the U.S. dollar;
- weaker macro-economic conditions in Japan combined with the limited release of manufacturing stimulus funds which, in turn, reduced industrial demand in Japan for capital purchases; and
- weaker industrial demand in Brazil due to recent macro-economic events.
FARO Technologies, Inc., together with its auxiliaries, designs, develops, manufactures, markets, and supports software driven, three-dimensional (3-D) measurement, imaging, and realization systems for manufacturing, industrial, architecture, surveying, building construction, and law enforcement applications.
At the end of Monday’s trade, Juno Therapeutics Inc (NASDAQ:JUNO)‘s shares dipped -13.55% to $55.90.
Juno Therapeutics Inc (JUNO) declared that it reached a settlement contract to resolve litigation with the Trustees of the University of Pennsylvania and Novartis Pharmaceuticals Corporation . Juno became a party to the litigation after it reached a December 2013 license contract with St. Jude Children’s Research Hospital, also a party in the litigation, for patent rights owned by St. Jude. The litigation itself, which began in July 2012 in connection with a contract dispute between St. Jude and Penn, was broadened in March 2013 to comprise a dispute concerning St. Jude’s U.S. Patent No. 8,399,645, titled “Chimeric Receptors with 4-1BB Stimulatory Signaling Domain.”
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI), ended its Monday’s trading session with -12.18% loss, and closed at $4.47.
Brainstorm Cell Therapeutics Inc (BCLI) declared that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Academy of Neurology annual meeting, taking place in Washington D.C. from April 18 to 25, 2015.
BrainStorm’s CEO Tony Fiorino, MD, PhD, commented “We are thrilled to have the opportunity to share our results at this prestigious venue, and we look forward to talk abouting these findings with the medical community.
Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing contract with Ramot of Tel Aviv University Ltd.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
